On September 10-12th 2025, the Nordic AML Group Meeting took its place in Bergen – Norway. The meeting was organised by the Nordic AML Group (https://www.namlg.org/) chaired by Professor Dr. med. Bjørn Tore Gjertsen. The K.G. Jebsen-Centre for Myeloid Blood Cancer (CMYC) contributed as the local organising committee, the technical organizer for the meeting, and sponsor of lectures.
With an inspiring program supplemented with a satellite Educational Day for physicians and a Nurse’s Day program aimed at nurses taking care of AML patients, the meeting brought together more than 150 participants from across the Nordic region and beyond, including leading minds, researchers, practitioners and innovators in the field of AML.
The meeting was highlighted with novel therapy in AML with focus on unfit and relapsed/refractory patients, and the current status of molecular genetics in AML diagnosis, measurable residual disease and therapy-guiding in the era of whole genome and transcriptome sequencing. Insights from on-going clinical trials, as well as emerging targets of epigenetics, non-coding genome, pseudomutant p53, and immunology in AML were also addressed. The panel discussion on recent advancements and challenges in treating relapsed/refractory AML patients in the Nordic region offered valuable insights.
The meeting was a great opportunity for participants from CMYC to present research findings with their posters, connect with colleagues and collaborators, and learn the latest advances in AML research and treatment strategies.
NB